Talis Biomedical is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. Co. is developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system comprises a compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. Co. is developing additional tests for infections related to women's health, including a panel for sexually transmitted infections and other infections. The TLIS average annual return since 2021 is shown above.
The Average Annual Return on the TLIS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TLIS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TLIS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|